Astellas’ drug Izervay, a treatment for eye condition geographic atrophy, has demonstrated an increase in efficacy over time according to 2-year data from the GATHER2 study. The drug’s effects were noted as early as six months, with significant impact doubling from year 1 to year 2. Izervay won FDA approval the previous year. However, the drug was not successful in reducing vision loss, an aspect that Astellas plans to investigate further. Izervay faces competition against Apellis’ Syfovre, with side effects being a critical factor in the rivalry. Recent reports of vision-threatening inflammation in patients receiving Syfovre could tip the balance in favor of Izervay.
To read more, click here.
[Source: Fierce Pharma, November 6th, 2023]